{"created":"2021-03-01T06:07:43.699278+00:00","id":3895,"links":{},"metadata":{"_buckets":{"deposit":"a3abc4d8-b3d6-4f4a-800c-810b324b830e"},"_deposit":{"id":"3895","owners":[],"pid":{"revision_id":0,"type":"depid","value":"3895"},"status":"published"},"_oai":{"id":"oai:soar-ir.repo.nii.ac.jp:00003895","sets":["461:462"]},"author_link":["7822","7823","7824","7825","7826","7827"],"item_1628147817048":{"attribute_name":"\u51fa\u7248\u30bf\u30a4\u30d7","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_6_biblio_info_6":{"attribute_name":"\u66f8\u8a8c\u60c5\u5831","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2009","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"180","bibliographicPageStart":"178","bibliographicVolumeNumber":"16","bibliographic_titles":[{"bibliographic_title":"Amyloid-Journal of Protein Folding Disorders"}]}]},"item_6_description_19":{"attribute_name":"\u5185\u5bb9\u8a18\u8ff0","attribute_value_mlt":[{"subitem_description":"This is an electronic version of an article published in Amyloid 2009, Vol. 16, No. 3 : Pages 178-180. Amyloid is available online at: http://informahealthcare.com/doi/pdf/10.1080/13506120903090940","subitem_description_type":"Other"}]},"item_6_description_20":{"attribute_name":"\u6284\u9332","attribute_value_mlt":[{"subitem_description":"We report a patient with AH amyloidosis associated with lymphoplasmacytic leukemia that has remained in a stable state with a nephrotic syndrome for 17 months since the commencement of cyclic rituximab therapy aimed at suppression of pathogenetic gamma heavy chains. Free light chains in serum and CD20-positive cells in peripheral blood were useful as hematological markers in the patient. Rituximab might be a potent therapeutic option for AH amyloidosis associated with a B-cell lymphoproliferative disorder.","subitem_description_type":"Abstract"}]},"item_6_description_30":{"attribute_name":"\u8cc7\u6e90\u30bf\u30a4\u30d7\uff08\u30b3\u30f3\u30c6\u30f3\u30c4\u306e\u7a2e\u985e\uff09","attribute_value_mlt":[{"subitem_description":"Article","subitem_description_type":"Other"}]},"item_6_description_5":{"attribute_name":"\u5f15\u7528","attribute_value_mlt":[{"subitem_description":"AMYLOID. 16(3):178-180 (2009)","subitem_description_type":"Other"}]},"item_6_link_3":{"attribute_name":"\u4fe1\u5dde\u5927\u5b66\u7814\u7a76\u8005\u7dcf\u89a7\u3078\u306e\u30ea\u30f3\u30af","attribute_value_mlt":[{"subitem_link_text":"Katoh, Nagaaki","subitem_link_url":"http://soar-rd.shinshu-u.ac.jp/profile/ja.yFTpgpkh.html"},{"subitem_link_text":"Yazaki, Masahide","subitem_link_url":"http://soar-rd.shinshu-u.ac.jp/profile/ja.gpTauakh.html"}]},"item_6_link_67":{"attribute_name":"WoS","attribute_value_mlt":[{"subitem_link_url":"http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000270909300008"}]},"item_6_publisher_4":{"attribute_name":"\u51fa\u7248\u8005","attribute_value_mlt":[{"subitem_publisher":"INFORMA HEALTHCARE"}]},"item_6_relation_47":{"attribute_name":"PubMed","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"19590993"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://pubmed.ncbi.nlm.nih.gov/19590993","subitem_relation_type_select":"PMID"}}]},"item_6_relation_48":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.1080/13506120903090940"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1080/13506120903090940","subitem_relation_type_select":"DOI"}}]},"item_6_source_id_35":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1350-6129","subitem_source_identifier_type":"PISSN"}]},"item_6_source_id_40":{"attribute_name":"\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID","attribute_value_mlt":[{"subitem_source_identifier":"AA11096426","subitem_source_identifier_type":"NCID"}]},"item_creator":{"attribute_name":"\u8457\u8005","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Katoh, Nagaaki","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Matsuda, Masayuki","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miyazaki, Daigo","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Gono, Takahisa","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yazaki, Masahide","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ikeda, Shu-ichi","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"\u30d5\u30a1\u30a4\u30eb\u60c5\u5831","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2015-09-24"}],"displaytype":"detail","filename":"Rituximab_therapy_nephrotic_syndrome.pdf","filesize":[{"value":"124.6 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"Rituximab_therapy_nephrotic_syndrome.pdf","url":"https://soar-ir.repo.nii.ac.jp/record/3895/files/Rituximab_therapy_nephrotic_syndrome.pdf"},"version_id":"dda89d9e-9739-4004-98ac-f56bb5ff20b3"}]},"item_keyword":{"attribute_name":"\u30ad\u30fc\u30ef\u30fc\u30c9","attribute_value_mlt":[{"subitem_subject":"AH amyloidosis","subitem_subject_scheme":"Other"},{"subitem_subject":"nephrotic syndrome","subitem_subject_scheme":"Other"},{"subitem_subject":"B-cell lymphoproliferative disorder","subitem_subject_scheme":"Other"},{"subitem_subject":"rituximab","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"\u8a00\u8a9e","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"\u8cc7\u6e90\u30bf\u30a4\u30d7","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Rituximab therapy in nephrotic syndrome due to AH amyloidosis","item_titles":{"attribute_name":"\u30bf\u30a4\u30c8\u30eb","attribute_value_mlt":[{"subitem_title":"Rituximab therapy in nephrotic syndrome due to AH amyloidosis","subitem_title_language":"en"}]},"item_type_id":"6","owner":"1","path":["461/462"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2011-01-12"},"publish_date":"2011-01-12","publish_status":"0","recid":"3895","relation_version_is_last":true,"title":["Rituximab therapy in nephrotic syndrome due to AH amyloidosis"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2021-09-02T07:48:17.855999+00:00"}